Inhibition of IκB Kinase (IKK) Protects Against Peripheral Nerve Dysfunction of Experimental Diabetes

Molecular Neurobiology

Volumn 51, Issue 2, 2015, Pages 591-598

  Negi, Geeta ^a   Sharma, Shyam S ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Diabetic neuropathy; IKK; I B; NF B; SC 514

Indexed keywords

I KAPPA B KINASE; SC 514; THIOPHENE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DRUG EFFECTS; ENZYMOLOGY; MALE; METABOLISM; NERVE CONDUCTION; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; I-KAPPA B KINASE; MALE; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, SPRAGUE-DAWLEY; THIOPHENES;

EID: 84934928477     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8784-8     Document Type: Article

References (36)

1. Ghosh S, May MJ, Kopp EB (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225–260. doi:10.1146/annurev.immunol.16.1.225
2. Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18:621–663. doi:10.1146/annurev.immunol.18.1.621
3. Hayden MS, Ghosh S (2012) NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 26(3):203–234. doi:10.1101/gad.183434.111
4. Karin M (1999) How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 18(49):6867–6874. doi:10.1038/sj.onc.1203219
5. Perkins ND (2012) The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 12(2):121–132. doi:10.1038/nrc3204
6. Scheidereit C (2006) IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 25(51):6685–6705. doi:10.1038/sj.onc.1209934
7. Gamble C, McIntosh K, Scott R, Ho KH, Plevin R, Paul A (2012) Inhibitory kappa B Kinases as targets for pharmacological regulation. Br J Pharmacol 165(4):802–819. doi:10.1111/j.1476-5381.2011.01608.x
8. Kim SG, Veena MS, Basak SK, Han E, Tajima T, Gjertson DW, Starr J, Eidelman O, Pollard HB, Srivastava M, Srivatsan ES, Wang MB (2011) Curcumin treatment suppresses IKKbeta kinase activity of salivary cells of patients with head and neck cancer: a pilot study. Clin Cancer Res 17(18):5953–5961. doi:10.1158/1078-0432.CCR-11-1272
9. Ziegelbauer K, Gantner F, Lukacs NW, Berlin A, Fuchikami K, Niki T, Sakai K, Inbe H, Takeshita K, Ishimori M, Komura H, Murata T, Lowinger T, Bacon KB (2005) A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 145(2):178–192. doi:10.1038/sj.bjp.0706176
10. Solinas G, Karin M (2010) JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction. FASEB J 24(8):2596–2611. doi:10.1096/fj.09-151340
11. van Diepen JA, Wong MC, Guigas B, Bos J, Stienstra R, Hodson L, Shoelson SE, Berbee JF, Rensen PC, Romijn JA, Havekes LM, Voshol PJ (2011) Hepatocyte-specific IKK-beta activation enhances VLDL-triglyceride production in APOE*3-Leiden mice. J Lipid Res 52(5):942–950. doi:10.1194/jlr.M010405
12. Negi G, Kumar A, Sharma SS (2011) Nrf2 and NF-κB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes. Curr Neurovasc Res 8(4):294–304. doi:10.2174/156720211798120972
13. Negi G, Kumar A, Kaundal RK, Gulati A, Sharma SS (2009) Functional and biochemical evidence indicating beneficial effect of Melatonin and Nicotinamide alone and in combination in experimental diabetic neuropathy. Neuropharmacology 58(3):585–592. doi:10.1016/j.neuropharm.2009.11.018
14. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32(1):77–88. doi:10.1016/0304-3959(88)90026-7
15. Negi G, Kumar A, Sharma SS (2010) Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy. Biochem Biophys Res Commun 391(1):102–106. doi:10.1016/j.bbrc.2009.11.010
16. Negi G, Kumar A, Sharma SS (2011) Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kappaB and Nrf2 cascades. J Pineal Res 50(2):124–131. doi:10.1111/j.1600-079X.2010.00821.x
17. Kumar A, Negi G, Sharma SS (2011) JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes Obes Metab 13(8):750–758. doi:10.1111/j.1463-1326.2011.01402.x
18. Cameron NE, Cotter MA (2008) Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets 9(1):60–67. doi:10.2174/138945008783431718
19. Israel A (2010) The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol 2(3):a000158. doi:10.1101/cshperspect.a000158
20. Karin M, Delhase M (2000) The IkB kinase (IKK) and NF-kB: key elements of proinflammatory signalling. Semin Immunol 12(1):85–98. doi:10.1006/smim.2000.0210
21. Gomez AB, MacKenzie C, Paul A, Plevin R (2005) Selective inhibition of inhibitory kappa B kinase-beta abrogates induction of nitric oxide synthase in lipopolysaccharide-stimulated rat aortic smooth muscle cells. Br J Pharmacol 146(2):217–225. doi:10.1038/sj.bjp.0706308
22. Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU, Brady JN (2005) A novel NF-kappaB pathway involving IKKbeta and p65/RelA Ser-536 phosphorylation results in p53 Inhibition in the absence of NF-kappaB transcriptional activity. J Biol Chem 280(11):10326–10332. doi:10.1074/jbc.M412643200
23. Kishore N, Sommers C, Mathialagan S, Guzova J, Yao M, Hauser S, Huynh K, Bonar S, Mielke C, Albee L, Weier R, Graneto M, Hanau C, Perry T, Tripp CS (2003) A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J Biol Chem 278(35):32861–32871. doi:10.1074/jbc.M211439200
24. Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R, Karin M (1999) The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 189(11):1839–1845. doi:10.1084/jem.189.11.1839
25. Gill JS, Windebank AJ (2000) Ceramide initiates NFkappaB-mediated caspase activation in neuronal apoptosis. Neurobiol Dis 7(4):448–461. doi:10.1006/nbdi.2000.0312
26. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, Schwaninger M (1999) NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat Med 5(5):554–559. doi:10.1038/8432
27. Boissiere F, Hunot S, Faucheux B, Duyckaerts C, Hauw JJ, Agid Y, Hirsch EC (1997) Nuclear translocation of NF-kappaB in cholinergic neurons of patients with Alzheimer’s disease. Neuroreport 8(13):2849–2852
28. Doyle T, Chen Z, Muscoli C, Obeid LM, Salvemini D (2011) Intraplantar-injected ceramide in rats induces hyperalgesia through an NF-kappaB- and p38 kinase-dependent cyclooxygenase 2/prostaglandin E2 pathway. FASEB J 25(8):2782–2791. doi:10.1096/fj.10-178095
29. Moser CV, Kynast K, Baatz K, Russe OQ, Ferreiros N, Costiuk H, Lu R, Schmidtko A, Tegeder I, Geisslinger G, Niederberger E (2011) The protein kinase IKKepsilon is a potential target for the treatment of inflammatory hyperalgesia. J Immunol 187(5):2617–2625. doi:10.4049/jimmunol.1004088
30. J-e Y, Yuan W, Lou X, Zhu T (2012) Streptozotocin-induced diabetic hyperalgesia in rats is associated with upregulation of toll-like receptor 4 expression. Neurosci Lett 526(1):54–58. doi:10.1016/j.neulet.2012.08.012
31. Nadjar A, Tridon V, May MJ, Ghosh S, Dantzer R, Amedee T, Parnet P (2005) NFkappaB activates in vivo the synthesis of inducible Cox-2 in the brain. J Cereb Blood Flow Metab 25(8):1047–1059. doi:10.1038/sj.jcbfm.9600106
32. Sorli CH, Zhang HJ, Armstrong MB, Rajotte RV, Maclouf J, Robertson RP (1998) Basal expression of cyclooxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet. Proc Natl Acad Sci U S A 95(4):1788–1793
33. Xie QW, Kashiwabara Y, Nathan C (1994) Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 269(7):4705–4708
34. Ramos KM, Jiang Y, Svensson CI, Calcutt NA (2007) Pathogenesis of spinally mediated hyperalgesia in diabetes. Diabetes 56(6):1569–1576. doi:10.2337/db06-1269
35. Bujalska M, Tatarkiewicz J, de Corde A, Gumulka SW (2008) Effect of cyclooxygenase and nitric oxide synthase inhibitors on streptozotocin-induced hyperalgesia in rats. Pharmacology 81(2):151–157. doi:10.1159/000110787
36. Matsunaga A, Kawamoto M, Shiraishi S, Yasuda T, Kajiyama S, Kurita S, Yuge O (2007) Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozotocin-induced mechanical hyperalgesia in rats. Eur J Pharmacol 554(1):12–17. doi:10.1016/j.ejphar.2006.09.072